文献速递骨质疏松与代谢性骨病创伤骨科

甲氨蝶呤骨病:五例病例及系统文献综述

Methotrexate osteopathy: five cases and systematic literature review.
PubMed 文献 · Osteoporos Int · 2020-10-30

患者表现为非典型部位骨折,停用甲氨蝶呤后均改善,部分使用抗骨吸收药物后仍复发。机制研究提示甲氨蝶呤可能对成骨细胞有剂量依赖性残留效应。

要点

  • 甲氨蝶呤骨病三联征为疼痛、骨质疏松和非典型应力性骨折,临床罕见但需认识。
  • 停用甲氨蝶呤后患者多可改善,但双膦酸盐治疗者仍可能发生非典型部位骨折复发。
  • 文献病例不一定伴骨密度降低,机制可能涉及成骨细胞减少和破骨细胞活性增加。

核心结论

  • 甲氨蝶呤骨病虽罕见,风湿科医生在使用甲氨蝶呤治疗炎症性疾病时应认识此病。
  • 其机制尚不明确,提示甲氨蝶呤可能对成骨细胞存在剂量依赖性残留效应。

研究设计与样本

  • 研究回顾了雷恩大学医院风湿科2011至2019年记录的5例甲氨蝶呤骨病病例,并进行系统文献综述。

主要发现

  • 5例患者骨折部位均非典型骨质疏松性骨折部位。
  • 所有患者停用甲氨蝶呤后数月内改善;除1例外均接受抗骨吸收治疗(双膦酸盐或地舒单抗)。
  • 2例接受双膦酸盐治疗的患者出现非典型部位骨折复发。
  • 细胞研究显示甲氨蝶呤主要导致生长板中成骨细胞、骨细胞和软骨细胞数量减少,破骨细胞数量和活性增加。
  • 体外机械刺激实验显示甲氨蝶呤存在时人小梁骨细胞机械转导改变,伴膜超极化,作用于整合素通路。

关键数值与推荐

  • 甲氨蝶呤骨病最初描述为疼痛、骨质疏松和非典型骨折三联征。
  • 文献中病例与本次报告不同,并不一致伴有骨密度降低。

临床怎么用

  • 使用甲氨蝶呤治疗炎症性疾病时,若出现疼痛或非典型骨折应警惕甲氨蝶呤骨病。
  • 怀疑甲氨蝶呤骨病时应考虑停用甲氨蝶呤,停药后多数患者可改善。
  • 使用双膦酸盐治疗者仍需监测非典型部位骨折复发。

局限性

  • 本研究为单中心病例系列,样本量小(5例)。
  • 文献综述病例与本次报告在骨密度变化上不一致。
  • 甲氨蝶呤骨病的病理生理机制仍知之甚少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Methotrexate (MTX)-related osteopathy is rare, defined by the triad of pain, osteoporosis, and "atypical fractures" when it was first described in the 1970s in children treated with high doses MTX for acute leukemia. Since then, several cases have been reported in patients treated with low-dose MTX for inflammatory diseases. METHODS: A systematic research of cases of MTX-related osteopathy was performed in records of Rheumatology Department of Rennes University Hospital. Data collection focused on demographic data, corticosteroid doses, MTX doses and intake method, cumulative doses, year of diagnosis, fracture location, bone densitometry value, and osteoporosis treatment if necessary. A literature review was also conducted to identify other cases in literature and try to understand the pathophysiological mechanisms of this rare entity. RESULTS: We report 5 cases identified between 2011 and 2019, which represents the largest cohort described excluding oncology cases. Fracture locations were atypical for osteoporotic fractures. All patients improved in the following months with MTX withdrawal. All patients except one were treated with antiresorptives (bisphosphonates, denosumab). Two patients, treated with bisphosphonates, had a recurrence of fracture, once again of atypical location. Twenty-five cases were collected in literature with similar clinical presentation. The cellular studies that investigated the bone toxicity of MTX mainly showed a decrease in the number of osteoblasts, osteocytes, and chondrocytes in the growth plate and an increase in the number and activity of osteoclasts. In vitro, consequences of mechanical stimulation on human trabecular bone cells in the presence of MTX showed an alteration in mechano-transduction, with membrane hyperpolarization, acting on the integrin pathway. In contrast with our report, the cases described in the literature were not consistently associated with a decrease in bone mineral density (BMD). CONCLUSION: MTX osteopathy while rare must be known by the rheumatologist, especially when using this treatment for inflammatory conditions. The mechanisms are still poorly understood, raising the question of a possible remnant effect of MTX on osteo-forming bone cells, potentially dose-dependent. Methotrexate (MTX) osteopathy, described as a clinical triad, pain, osteoporosis, and atypical stress fractures, while rare, must be known by the rheumatologist. Our cohort of 5 cases represent the largest series of the literature. Pathophysiological studies raised the question of a dose-dependent remnant effect of MTX on osteo-forming bone cells.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Robin F, Cadiou S, Albert JD, et al. Methotrexate osteopathy: five cases and systematic literature review. Osteoporos Int. 2020. PMID: 33128074. doi:10.1007/s00198-020-05664-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。